Journal of Clinical & Experimental Dermatology Research
Open Access
ISSN: 2155-9554
+44 1478 350008
ISSN: 2155-9554
+44 1478 350008
Hok Bing Thio
Erasmus University Medical Centre, Netherlands
Posters & Accepted Abstracts: Clin Exp Dermatol Res
Psoriasis is a chronic, immune mediated inflammatory skin disease, characterized by hyperproliferation of keratinocytes and an increased dermal infiltration of immunologically active cells. Most patients with moderate to severe disease require longterm systemic treatment to control their psoriasis. Fumarates (dimethylfumarate (DMF) and monoethylfumarate (MEF)) are small molecules used as oral treatment in psoriasis for more than 25 years, mainly in Western Europe. Clinical studies have shown that 50 to 70% of fumarates treated psoriasis patients show a clinical improvement of at least 70% following 16 weeks of treatment. Data from long-term observational studies on treatment of psoriasis with fumarates indicate a favorable safety profile. In vitro studies have shown that DMF inhibits dendritic cell maturation and keratinocyte proliferation. DMF has several effects on mitochondria and signal transduction pathways. More recently DMF is registered as systemic therapy for relapsing-remitting multiple sclerosis.
Email: h.thio@erasmusmc.nl